Condition (MeSH)
Sarcoma, Ewing
ClinicalTrials.gov lists 244 trials for Sarcoma, Ewing or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 31.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
1 more section with rows
244 of the 244 trials are tagged with Sarcoma, Ewing itself; the rest are tagged with a narrower condition beneath it.
When did Sarcoma, Ewing trials start? (32)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 4 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 18
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 14 |
| 2025 | 11 |
| 2024 | 15 |
| 2023 | 12 |
| 2022 | 10 |
| 2021 | 18 |
| 2020 | 15 |
| 2019 | 5 |
| 2018 | 18 |
| 2017 | 11 |
Showing 10 of 32 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 16 trials starting in 2026 and about 14 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Prediction, not a registry value: median of 36 months from start to primary completion across 43 trials still running at the 2026-10-09 snapshot; registered median of 51 months across 132 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sarcoma, Ewing trials in? (9)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 66 |
| Phase 1/2 | 40 |
| Phase 2 | 69 |
| Phase 2/3 | 2 |
| Phase 3 | 7 |
| Phase 4 | 1 |
| Not applicable | 22 |
| Observational | 34 |
| Expanded access | 3 |
How many Sarcoma, Ewing trials are recruiting? (10)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 9 |
| Recruiting | 55 |
| Active, not recruiting | 27 |
| Completed | 102 |
| Suspended | 1 |
Showing 5 of 10 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sarcoma, Ewing trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 31 |
| Children's Oncology Group | 6 |
| Gradalis, Inc. | 5 |
| Eli Lilly and Company | 4 |
| Italian Sarcoma Group | 3 |
Which drugs are being tested for Sarcoma, Ewing? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 19 |
| Irinotecan | 18 |
| TOPOTECAN | 8 |
| Melphalan | 8 |
| Busulfan | 6 |
Showing 5 of 6 drugs.
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| SOC: Temozolomide | 18 |
| Vincristina | 13 |
| Doxorubicine | 11 |
| Etoposid | 7 |
| Ifosfamid | 6 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Sarcoma, Ewing trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pleural effusion | 73 | 22 |
| Disease progression | 61 | 12 |
| Dyspnea | 57 | 13 |
| Vomiting | 57 | 17 |
| Febrile neutropenia | 54 | 14 |
Showing 5 of 10 adverse events.
Which publications cover Sarcoma, Ewing? (180)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial. | British journal of cancer | 2026 | Yes |
| Intensified Induction Therapy for Newly Diagnosed, Localized Skeletal Ewing Sarcoma (ISG/AIEOP EW-1): A Randomized, Open-Label, Phase 3, Non-Inferiority Trial. | Pediatric blood & cancer | 2025 | Yes |
| Consensus recommendations regarding local and metastasis-directed therapies in the management of relapsed/recurrent Ewing sarcoma. | Cancer | 2025 | Yes |
| A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors. | Pediatric blood & cancer | 2025 | Yes |
| Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium. | JCO precision oncology | 2025 | Yes |
Showing 5 of 180 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Skeletal Ewing sarcoma | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Skeletal Ewing sarcoma | Annual incidence | 1-9 / 1 000 000 | Europe | Not stated | Unspecified |
| Skeletal Ewing sarcoma | Lifetime prevalence | 1-9 / 100 000 | Europe | Not stated | Unspecified |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity and sub-conditions in mesh.